Home Companies Catalysts Deep Dives
Truqap capivasertib APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Launch2023-11-16
US LOE2036-01-01
Peak Sales Est$2000M
Formulations[{"id":"truqap-oral","doses":"160mg tablets","route":"Oral","setting":"PATIENT_SELF","frequency":"Tw
Companies
AZN (ORIGINATOR)100%
Mechanism: AKT inhibitor
Expert: Selective ATP-competitive pan-AKT kinase inhibitor that blocks PI3K/AKT pathway signaling in tumors with PIK3CA/AKT1/PTEN alterations.
Everyday: Blocks a protein that helps cancer cells grow and resist treatment.
Targets: ["AKT"]
Revenue History
PeriodRevenue ($M)
2024$185M
Q1 2025$75M
Q2 2025$95M
Programs (1)
IndicationStageKey StudyRegional Status
HR+/HER2- BCAPPROVEDCAPItello-291[{"stage":"APPROVED","region":"US","approval_date":"2023-11-16"},{"stage":"APPRO
Notes
AKT inhibitor for breast cancer.
Data from Supabase · Updated 2026-03-24